Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease
2024; Lippincott Williams & Wilkins; Volume: 102; Issue: 4 Linguagem: Inglês
10.1212/wnl.0000000000209131
ISSN1526-632X
AutoresMatthew Adesuyan, Yogini Jani, Dana Alsugeir, Robert Howard, Chengsheng Ju, Li Wei, Ruth Brauer,
Tópico(s)Blood Pressure and Hypertension Studies
ResumoRepurposing phosphodiesterase type 5 inhibitors (PDE5Is) as drugs for Alzheimer disease (AD) risk reduction has shown promise based on animal studies. However, evidence in humans remains inconclusive. Therefore, we conducted a cohort study to evaluate the association between PDE5I initiation compared with nonuse and the risk of developing AD in men with erectile dysfunction (ED).
Referência(s)